Search results
AHRQ survey: 7% of US adults reported having long COVID by early 2023
Center for Infectious Disease Research and Policy· 3 days ago"MEPS did not find that booster shots were associated with a reduced risk of having had COVID......
Past COVID infections may help protect against certain colds
WJTV Jackson· 21 hours agoResearchers linked the protection against coronavirus-caused colds to virus-killing cell responses...
COVID Long-Hauler’s Symptoms Significantly Improved with Psilocybin, MDMA
High Times· 7 days agoA 41-year-old woman in a case study reported remarkable improvements of longhauler’s symptoms after taking psilocybin and MDMA-assisted therapy sessions. A case report, “Long-COVID& ...
Ozempic, Wegovy, Mounjaro popularity soar as weight loss wonders
Pittsburgh Tribune-Review· 11 hours agoFor Diane Lang, the big push to focus on her health and weight came from her grandchildren. Lang, of...
Congenital Pigment Disorders May Need Special Management
Medscape· 17 hours agoCongenital disorders of pigmentation are numerous and can have mild to severe effects, and some have...
How Common Is Long COVID?
Journal of the American Medical Association· 7 days agoThis Medical News article discusses new US household survey data that found differences in long COVID rates based on preexisting chronic conditions and other factors.
Nike loses EU trademark case over ‘footware’ - The Boston Globe
The Boston Globe· 23 hours agoA newly constructed residential building in suburban Tokyo will be pulled down the month before the...
Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape· 4 days agoEncouraging phase 2 results of tirzepatide in the resolution of MASH and improvement in fibrosis...
Psoriasis After COVID-19: Is There a Connection?
Healthline· 7 days agoA few studies suggest some people with psoriasis may experience flares after getting COVID-19 or the vaccine. Psoriasis is a common autoimmune condition...
FDA OKs Iqirvo, First-in-Class PPAR Treatment for PBC
Medscape· 3 days agoIqirvo (elafibranor) is indicated for adults with primary biliary cholangitis who do not respond to or cannot tolerate ursodeoxycholic acid.